Ticiana A. Leal, MD

Articles

Predictors of Immunotherapy Response in Limited and Extensive SCLC

July 9th 2024

Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.

Examining 3-Year Update Data from the CASPIAN Trial

July 2nd 2024

A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

July 2nd 2024

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.

ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

June 25th 2024

Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.

Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

June 25th 2024

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

Dr Leal on the Utility of Patritumab Deruxtecan in EGFR+ NSCLC

April 3rd 2024

Ticiana Leal, MD, discusses the investigation of patritumab deruxtecan in the HERTHENA-Lung01 study in advanced EGFR-mutated non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Ongoing Research on HER3-DXd in NSCLC

November 9th 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

Role of HER3-DXd in Advanced NSCLC Treatment Landscape

November 2nd 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

NSCLC: Safety Outcomes from HERTHENA-Lung01

November 2nd 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

HERTHENA-Lung01: Patritumab Deruxtecan in Advanced EGFR-Mutated NSCLC

October 26th 2023

Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.

The Role of HER3 in Non–Small Cell Lung Cancer

October 26th 2023

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Treatments and Unmet Needs for EGFR-Mutated NSCLC

October 19th 2023

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

EGFR-Mutated NSCLC: Treatment Options Following Progression on Osimertinib

October 19th 2023

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Treatment Options for EGFR-Mutated NSCLC Following Progression

October 12th 2023

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

Current Treatment Landscape for EGFR-Mutated NSCLC

October 12th 2023

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Dr Leal on a PD-L1 Subgroup Analysis of the LUNAR Trial in mNSCLC

September 12th 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Novel HER2-Targeted Therapies for NSCLC

October 17th 2022

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

October 17th 2022

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Unmet Needs in NSCLC Therapy

October 17th 2022

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.